CDK4 and non-small cell lung carcinoma: Increasing evidence suggests that CDK4/6 inhibitors hold significant promise in the treatment of other cancers such as non-small cell lung cancer [33], esophageal cancer [34], and pancreatic ductal adenocarcinoma [35].